Thu, Dec 25, 2014, 9:22 PM EST - U.S. Markets closed for Christmas


% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • joynlight77 joynlight77 Oct 4, 2012 12:56 PM Flag

    UT SD article page 3

    “If you look at the nature of data in initial studies with small patient size, once you see efficacy, that is the most important sign, (which is) very encouraging. Then you wait for larger studies to see if it is reinforced,” said Yale Jen, senior biotech analyst with Roth Capital.

    “In terms of technology, this is a simple treatment modality. If clinical results bear out, this will be a very useful approach to treat patients.”

    Jen has a buy rating on the company’s stock, with a target price of $1 in the next year. Other analysts have set a target price of $2 and $2.50. The shares closed Tuesday at 24 cents, rising 2 cents.

    Roth said Dhillon has put together a good team and is focused on needs to get done.

    “Oncology has become a very important, interesting market,” he said. “When I began my career, there was just one company — Bristol Myers — but now that’s changed, there’s many ways beyond chemotherapy to treat tumors. Anything that improves outcomes with less side effects is going to have a good market.”

0.4525+0.0025(+0.56%)Dec 24 12:58 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST